Cite
MLA Citation
B Bressler et al.. “P419 Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn's disease patients: results from the EVOLVE study.” Journal of Crohn's and colitis, vol. 14, n.d., pp. S381–S382. http://access.bl.uk/ark:/81055/vdc_100099171270.0x000046